Vascular Surgery Research 1.888.287.1082 Text Size
Our Physicians & Staff
David M. Williams, M.D.
Professor of Radiology

Practicing at:
Academic Office: (734) 615-4890
Fax: (734) 936-4536
biography research

Aortic Dissection

Since 1989, the focus of my research has been the pathophysiology and catheter-based treatment of aortic disease, including aortic dissection, penetrating ulcers of the aorta, aortoiliac occlusive disease, atypical dissection, and aortic aneurysms. Our work on the physical and hemodynamic basis of balloon fenestration of aortic dissections has formed the basis of several clinical publications in the treatment of ischemic complications of aortic dissection.

Aortic Aneurysm

The development of stent-grafts for the endovascular treatment of aneurysms has made it critical to understand the pathophysiology of aneurysm development and growth. Our current research involves a careful comparison of surgical and autopsy specimens of aortic aneurysms with preoperative serial CT scans, and has uncovered a novel mechanism of aneurysm growth.

My primary clinical interest is the treatment of vascular disease, particularly the catheter-based diagnosis and treatment of aortic dissection and aneurysms, aortic branch artery occlusions and stenosis (including renovascular hypertension and mesenteric ischemia), and central venous recanalization (including iliac, axillary, and subclavian veins, and the inferior and superior vena cava). We are currently an investigational site for several endovascular devices. Those listed are being used under FDA-approved protocols. Study design and eligibility criteria (inclusion and exclusion criteria) can be inspected by referencing the protocol below:

  1. stent-graft for treatment of abdominal aortic aneurysms (Vanguard, Boston Scientific)
  2. stent-graft for the treatment of iliac artery occlusive disease (Wallgraft, Schneider)
  3. stent-graft for aortic branch artery pseudoaneurysms and arterial trauma (Wallgraft, Schneider)
  4. stent-graft for lesions in arteries (up to 11 mm diameter) when no surgical treatment is feasible and when patient does not fit protocols 2-3 above.
  5. stent for treatment of proximal atherosclerotic narrowing of the renal arteries which fail angioplasty (Palmaz stent, Johnson & Johnson).